Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-712 dose-escalation and expansion study in advanced relapsed or refractory cancers
jRCT2080224127Phase 1Completed
- Sponsor
- Chordia Therapeutics Inc.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rogocekib in Nonhematologic neoplasms, ovarian cancer, endometrial cancer (EC) and 6 more (5 cohorts), sponsored by Chordia Therapeutics Inc. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose and 1 more. Started Oct 2018; status: completed.
02
Drugs
rogocekib
03
Conditions
Nonhematologic neoplasmsovarian cancerendometrial cancer (EC)prostate cancer (PCa)breast cancer
Beyond the preview
Go deeper on jRCT2080224127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224127.